The Intelligent Transformation of Neuronal Cell Therapy
SigNAiture
Objective Diagnostics of Neuronal Cellular Pathways
Patient or Healthy Donor
Somatic Cells
Reprogram
iPSC
Neuronal Differentiation
Optional
Gene Edit
Predictive Biometric Diagnostic Map
SigNAiture Analysis
Physician/Clinician/Partner
Cell Collection
Global physician network provides controlled samples of skin, blood, or bone marrow
Theranostic Analysis
Objective Neuron Phenotype Diagnosis and Therapy Analysis
SigNAiture
Objective Phenotypic Deep Learning Powered Biometrics
Phenotyping
Operetta® CLS™
High throughput microplate imager for high-content analysis (HCA). Allows for Deep Learning and visualization of phenotypic parameters.
Phenotypic Parameters
Neural Network Dynamics
Cell Differentiation Genotypic Parameters
Quantification of Gene Expression
HD-MEA/Raman
High Definition Micro Electrode Array and Raman Spectroscopy. Discover novel subgroups of diseases. Examine drug response. Classify patients into disease groups. Predict disease outcomes.
Gene Editing
CRISPR/TALEN
Group of technologies to modify an organism's DNA. Allows genetic material to be added, removed, or altered at particular locations in the genome.
Ai Deep Learning Neural Network Algorithms
Digital PCR
Digital PCR
Provides ultrasensitive and absolute nucleic acid quantification. This technique is particularly useful for low abundance targets, and allelic variants (SNPs) and for monitoring of subtle changes in mRNA levels
Management Team
ROBERT KONOPACZ, CEO
Bob Konopacz brings more than 40 years of experience in biotechnology and Advanced Medicine which includes work with the development and approval of the CAR-T therapeutic Kymriah at Novartis AG, Rubius Therapeutics, and Genetics Institute (Pfizer),. Bob was an original member at Genentech, Bob holds a B.S. in Chemical Engineering and a B.S. in Microbiology from Michigan State University
SETH YAKATAN, CFO
Seth Yakatan brings more than 20 years of experience as a corporate finance professional, actively supporting small cap and major companies in achieving corporate, financing and asset monetization objectives through the successful structuring and management of strategic transactions and investments totaling more than several billion dollars in value.
​
JAMES BROWN, Director
James Brown is a founder of Agathos Biologics and currently serves as CEO. He has held multiple leadership roles at Aldevron, REGENXBIO and assurance at MedImmune (now AstraZeneca). James is dedicated to creating ethical biotechnology products and services. He holds a Ph.D. in chemistry from Stanford University and a B.S. in chemistry from Butler University.​
